title: [Pilot study of dementia medication compliance conducted among pharmacists providing home visits which evaluates the degree of drug compliance, as defined by numerous attributes, between patients at home and patients in a medical facility].
abstract: A survey was conducted among pharmacists providing "home-visit guidance on drug management" to patients taking medication for dementia. Factors related to medication adherence among patients and pharmacists' acquisition of patient information were then verified. The survey items were: (1) patient attributes (degree of care received, bed-ridden, family composition, and living environment); (2) the person controlling medications; (3) drug storage method and location; (4) dispensing method; (5) patient management of visiting nurses; (6) patient management of visiting physician; (7) details of pharmacist's home-visit guidance; (8) medication adherence; (9) five items related to cognitive function (short-term memory, autonomous judgment, fluctuations in level of consciousness, excitation and loss of orientation, understanding); and (10) ten items related of ADL (mobility in bed, transferring, mobility within the home or outdoors, dressing upper/lower body, eating, toilet use, individual hygiene, bathing). The t test was used to verify the number of items of patient information concerning cognitive function and physical function that pharmacists could acquire at a visit. It was suggested that pharmacists were able to acquire more patient information (①cognitive function and ②ADL) when they visited patients cared for at home, compared to facility residents (①p=0.008, ② p=0.006). Thus, it was suggested that there is a latent risk concerning the pharmacist's ability to discover problems with administration of medications among facility residents. These findings demonstrate that it is essential for pharmacists to be more proactive about providing home-visit guidance.
authors.affiliation: Advance Pharma Research Office, Nara, Japan.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Nanaumi
authors.forename: Shunya
authors.initials: S
authors.lastname: Matoba
authors.forename: Mitsuko
authors.initials: M
authors.lastname: Onda
authors.forename: Rie
authors.initials: R
authors.lastname: Tanaka
authors.forename: Kenichi
authors.initials: K
authors.lastname: Tsubota
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Mukai
authors.forename: Hidehiko
authors.initials: H
authors.lastname: Sakurai
authors.forename: Yukitoshi
authors.initials: Y
authors.lastname: Hayase
authors.forename: Yukio
authors.initials: Y
authors.lastname: Arakawa
mesh_terms: D000203:Activities of Daily Living; D003071:Cognition; D003704:Dementia / Q000188:drug therapy* / Q000523:psychology*; D000077265:Donepezil; D006268:Health Facilities; D006792:House Calls; D006801:Humans; D007189:Indans / Q000008:administration & dosage*; D018697:Nootropic Agents / Q000008:administration & dosage*; D010346:Patient Care Management; D010349:Patient Compliance; D010595:Pharmacists; D010865:Pilot Projects; D010880:Piperidines / Q000008:administration & dosage*; D024382:Professional Role
chemical_list: D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil